about
Differential inhibition of receptor activation by two mouse monoclonal antibodies specific for the human leukotriene B4 receptor, BLT1.Impaired Coronary and Renal Vascular Function in Spontaneously Type 2 Diabetic Leptin-Deficient Mice.Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes.The effects of dual PPARα/γ agonism compared with ACE inhibition in the BTBRob/ob mouse model of diabetes and diabetic nephropathy.Long noncoding RNAs are dynamically regulated during β-cell mass expansion in mouse pregnancy and control β-cell proliferation in vitro.Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes.Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency.Cloning of a novel chemoattractant receptor activated by leukotriene B4 and used by human immunodeficiency virus type 1 to infect CD4-positive immune cells. A therapeutic connection to asthma?Non-specific effects of leukotriene synthesis inhibitors on HeLa cell physiology.15-deoxy-Delta12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells.Target Deconvolution Efforts on Wnt Pathway Screen Reveal Dual Modulation of Oxidative Phosphorylation and SERCA2.Leukotriene B4 is the functional ligand binding to and activating the cloned chemoattractant receptor, CMKRL1.Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease.Fluorescent leukotriene B4: potential applications.Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses.Pro- and anti-inflammatory substances modulate expression of the leukotriene B4 receptor, BLT1, in human monocytesResidues from transmembrane helices 3 and 5 participate in leukotriene B4 binding to BLT1
P50
Q31028381-16FB01E0-4BA1-4AD3-AB8A-72DECA950721Q35670472-64A4BCE1-0AD9-4403-A30A-C55EEAA9E7D1Q37348520-0DA7E865-3239-4296-8045-9092EF4AEA6FQ37699675-255B0EC6-5FFD-4172-9F0B-29A57265623EQ38695228-5A1F97E5-78E5-45F1-8A7A-EC152137F560Q38756737-07160D5E-6BE9-4F4F-BAE5-B1877D4963EEQ38979558-9AFD9FBC-46CE-479A-9B3E-93722E9DDC4BQ42600049-34E4AB27-CA1F-40B2-99DD-52822F639096Q45744476-391B3B51-AC95-41E1-87B0-3BCA9E16CB0AQ46711121-89B2E423-0BCF-4C20-BA58-EA893B854DC7Q46958393-9295A35D-8017-47EB-973E-0AD3A9665DA3Q48328469-EFEB7700-CCF7-417D-944F-86B38F0794C7Q48771916-7DD5E487-8E2D-4F8A-B468-5100AD59A2D5Q49120393-661ACDB0-02FD-4080-95FA-566373EFB3B4Q50773065-945EAF69-193E-46C3-A554-E51288435506Q53558365-21D8FC78-F8C7-4D81-9FE3-9CE912586E53Q81435312-ECD9BD3B-1575-415F-9EB4-91AD1D879330Q83274862-13FBB4B4-A997-424F-85A8-F566EF0C899A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alan Sabirsh
@ast
Alan Sabirsh
@en
Alan Sabirsh
@es
Alan Sabirsh
@nl
Alan Sabirsh
@sl
type
label
Alan Sabirsh
@ast
Alan Sabirsh
@en
Alan Sabirsh
@es
Alan Sabirsh
@nl
Alan Sabirsh
@sl
prefLabel
Alan Sabirsh
@ast
Alan Sabirsh
@en
Alan Sabirsh
@es
Alan Sabirsh
@nl
Alan Sabirsh
@sl
P106
P21
P31
P496
0000-0001-5310-0281